Physician profile
Jeffrey Wayne Elder
NPI 1457569923
$1,966.80
in general payments reported to CMS, 2019-2025
36 companies · $566 in 2025
The $566 reported for 2025 was more than what a typical Gynecologic Oncology provider received nationally (typical 2025 total: $305).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $212 · 2020: $233 · 2021: $151 · 2022: $46.37 · 2023: $313 · 2024: $446 · 2025: $566.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,324.12 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $253.43 | 2019-2025 | Lynparza, Tagrisso |
| Eisai INC. | $206.58 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $196.86 | 2020-2025 | Keytruda, Lenvima, Keytruda Qlex |
| Glaxosmithkline, LLC. | $139.49 | 2021-2025 | Zejula, Jemperli |
| Myriad Genetic Laboratories, INC. | $135.83 | 2021-2025 | Myrisk |
| Daiichi Sankyo INC. | $129.40 | 2023-2025 | Enhertu |
| Clovis Oncology, INC. | $118.36 | 2020 | |
| Amgen INC. | $109.26 | 2019 | |
| Novartis Pharmaceuticals Corporation | $78.59 | 2023-2024 | |
| Pfizer INC. | $53.47 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $52.42 | 2025 | |
| Abbvie INC. | $47.66 | 2025 | |
| Lilly USA, LLC | $32.66 | 2023 | Jaypirca, Retevmo, Verzenio |
| Baxter Healthcare | $31.94 | 2024 | Perclot |
| Seagen INC. | $30.43 | 2023 | Tukysa, Adcetris |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pharmacosmos Therapeutics INC. | $27.78 | 2025 | Monoferric |
| Genmab U.S., INC. | $26.05 | 2023 | Tivdak |
| Dendreon Pharmaceuticals LLC | $23.76 | 2024 | Provenge |
| Ipsen Biopharmaceuticals, INC | $22.23 | 2024 | Somatuline Depot, Onivyde |
| Regeneron Healthcare Solutions, INC. | $22.14 | 2023 | Libtayo |
| Geron Corporation | $22.13 | 2025 | Rytelo |
| Taiho Oncology, INC. | $21.68 | 2024 | |
| Rigel Pharmaceuticals, INC. | $20.60 | 2025 | Rezlidhia, Tavalisse, Gavreto |
| Genentech USA, INC. | $19.63 | 2024 | Perjeta, Phesgo |
| G1 Therapeutics, INC. | $19.60 | 2023 | Cosela |
| Alnylam Pharmaceuticals INC. | $19.05 | 2025 | Givlaari |
| Sanara Medtech INC. | $18.55 | 2025 | Celleraterx |
| Incyte Corporation | $15.14 | 2020 | |
| Tersera Therapeutics LLC | $15.03 | 2025 | Zoladex |
| Stemline Therapeutics INC. | $14.39 | 2023 | Orserdu |
| Delcath Systems | $13.66 | 2025 | Hepzato Kit |
| Foundation Medicine, INC. | $13.26 | 2023 | |
| Coherus Oncology, INC. | $12.02 | 2021 | |
| Intuitive Surgical, INC. | $3.72 | 2024 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Elder listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.